Fourteen of 20 (70.0 %) RCC patients received a prior anti-VEGF treatment [16 (80.0 %) were clear cell carcinoma, three (15.0 %) papillary and one (5.0 %) clear cell + chromophobe RCC]. This evidence concerns the gene VEGFA and clear cell adenocarcinoma.